KT-333 / Kymera Therap - LARVOL DELTA

A STAT3 Degrader Demonstrates Pre-Clinical Efficacy in Venetoclax Resistant Acute Myeloid Leukemia (ASH 2023) - P1 | "Ven is FDA approved in combination with hypomethylating agents (HMA's) or low dose cytarabine for the treatment of de-novo AML in patients > 75 years or those ineligible for standard induction therapies...Additionally, cell derived xenograft (CDX) models of Ven-res showed significant reduction of pTyr-705 STAT3(~60%), total STAT3 (>90%) and MCL1 (~70%), on treatment with STAT3 degrader - KT-333 (currently in an early phase clinical trial:NCT05225584), as early as week 2 (Fig 1B). Our study suggests that targeting STAT3 and the downstream MCL1 represents a novel and effective strategy for Ven-resistant AML patients in clinic, with strong mechanistic rationales that can spur further clinical development of STAT3 degraders especially given the significant side effects of direct MCL1 inhibitors."

IO biomarker • Preclinical • Acute Myelogenous Leukemia • Anemia • Hematological Disorders • Hematological Malignancies • Leukemia • Lymphoma • Oncology • IL6 • STAT3

Preliminary Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia, and Solid Tumors (ASH 2023) - P1 | "The emerging clinical data demonstrate that KT-333 is a potent degrader of STAT3 as demonstrated in PBMCs at doses that are well tolerated. These data provide the first evidence of STAT3 targeted protein degradation in humans with associated STAT3 pathway inhibition, along with potential early signs of antitumor activity, highlighting the potential of heterobifunctional degraders for targeting previously undruggable transcription factors implicated in diseases. Based on non-clinical data and PK/PD modeling, the high levels of degradation achieved so far are expected to be clinically efficacious in STAT3-dependent malignancies."

Clinical • IO biomarker • PK/PD data • Anemia • B Cell Non-Hodgkin Lymphoma • Constipation • Cutaneous T-cell Lymphoma • Fatigue • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma • Prolymphocytic Leukemia • Solid Tumor • T Cell Non-Hodgkin Lymphoma • Targeted Protein Degradation • CRP • SOCS3 • STAT3

Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Leukemia, and Solid Tumors (ASH 2024) - P1 | "These results highlight the potential of heterobifunctional degraders to successfully target previously undrugged transcription factors implicated in cancer. Accrual is ongoing, and further analyses will be presented at the meeting."

Clinical • IO biomarker • PK/PD data • B Cell Non-Hodgkin Lymphoma • Classical Hodgkin Lymphoma • Constipation • Cutaneous T-cell Lymphoma • Dental Disorders • Fatigue • Gastroenterology • Gastrointestinal Disorder • Hematological Malignancies • Hodgkin Lymphoma • Leukemia • Lymphoma • Musculoskeletal Pain • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma • Prolymphocytic Leukemia • Solid Tumor • Stomatitis • T Cell Non-Hodgkin Lymphoma • IFNG • JAK2 • PD-L1 • PD-L2 • SOCS3 • STAT3

KT333-TL-101: Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients with Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors (clinicaltrials.gov) - P1 | N=56 | Completed | Sponsor: Kymera Therapeutics, Inc. | Active, not recruiting ➔ Completed | N=120 ➔ 56

Enrollment change • Trial completion • Chronic Lymphocytic Leukemia • Cutaneous T-cell Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Indolent Lymphoma • Leukemia • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma • Prolymphocytic Leukemia • Solid Tumor • T Cell Non-Hodgkin Lymphoma • T-Cell Large Granular Lymphocyte Leukemia • B3GAT1 • CD8

Breakthroughs in treatment for hematological malignancies: latest updates on molecular glue, PROTACs and RNA degraders from ASH 2024. (PubMed, J Hematol Oncol) - "Currently, the main categories developed based on degraders include molecular glue (such as Cemsidomide, NX-5948), PROTACs (such as BGB-16673, AC-676, KT-333 ), and RNA degraders (such as SKY-1214). This correspondence summarizes the preclinical and clinical updates on degrader therapies presented at the ASH 2024 annual meeting."

Journal • Review • Acute Myelogenous Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology • Targeted Protein Degradation

KT333-TL-101: Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients with Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors (clinicaltrials.gov) - P1 | N=120 | Active, not recruiting | Sponsor: Kymera Therapeutics, Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Chronic Lymphocytic Leukemia • Cutaneous T-cell Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Indolent Lymphoma • Leukemia • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma • Prolymphocytic Leukemia • Solid Tumor • T Cell Non-Hodgkin Lymphoma • B3GAT1 • CD8

Kymera Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire) - "Dose escalation and enrollment have been completed for both the KT-333 and KT-253 Phase 1 trials. Based on an overall assessment of its clinical oncology programs, and given progress across the immunology pipeline, the Company has made the strategic decision not to continue development of KT-333 (STAT3) and KT-253 (MDM2) beyond Phase 1. Kymera plans to present STAT3 Phase 1 data at a poster presentation at ASH in December. The Company is evaluating partnership opportunities to advance the oncology pipeline beyond its current stage."

Discontinued • Trial status • Acute Lymphocytic Leukemia • Cutaneous T-cell Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma • Solid Tumor

A STAT3 Degrader Demonstrates Pre-clinical Efficacy in Venetoclax resistant Acute Myeloid Leukemia. (PubMed, bioRxiv) - "Treatment with a clinical-stage STAT3 degrader, KT-333 resulted in a significant reduction in STAT3 and MCL1 protein levels within two weeks of treatment in a cell derived xenograft model of Ven-res AML. Our prior research demonstrated STAT3 over-expression in AML HSPC's to be associated with inferior survival. We now explore STAT3 over-expression in Ven-res AML, explain STAT3 mediated mitochondrial perturbations and describe a novel therapeutic strategy, STAT3 degradation to overcome Ven-res."

IO biomarker • Journal • Preclinical • Acute Myelogenous Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Metabolic Disorders • Oncology • MCL1 • STAT3

Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting (GlobeNewswire) - "Kymera Therapeutics, Inc...announced that new preclinical data showing the structural and molecular mechanisms underlying anti-tumor activity of its novel STAT3 degrader, KT-333, were presented in a late-breaking research poster session at the AACR Annual Meeting taking place April 5-10, 2024, in San Diego, California. Additionally, Nello Mainolfi, PhD, Founder, President and CEO, will present in the Major Symposium at the conference highlighting the Company’s unique target selection strategy and strong preclinical to clinical translation observed across the Company’s first-in-class oncology programs, KT-333 and KT-253, a potent and selective degrader of MDM2.... In the STAT3-dependent SUDHL-1 lymphoma xenograft model, reduced expression of canonical STAT3 targets and down-regulation of cytokine-mediated signaling and cell cycle signature genes indicated that cell cycle arrest and subsequent apoptosis were the main drivers of efficacy for KT-333."

Late-breaking abstract • Preclinical • Hematological Malignancies • Lymphoma • Oncology • Von Hippel-Lindau Syndrome

Kymera Therapeutics Announces Second Quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire) - "Dose escalation in the KT-253 Phase 1a clinical trial is ongoing in both Arm A (solid tumors and lymphomas) and Arm B (high grade myeloid malignancies). The Company expects to complete enrollment in the second half of 2024 and subsequently to share the Phase 1a data set as well as guidance on next development steps. Kymera is developing a biomarker-based patient selection strategy for subsequent development beyond Phase 1a and plans to present data later in 2024 at a medical meeting....STAT3 Degrader Program: The Phase 1a clinical trial is ongoing with enrollment focused on Hodgkin’s lymphoma based on encouraging clinical responses. Additionally, the Company is exploring opportunities for future expansion into solid tumors in combination with immune checkpoint inhibitors and other targeted therapies. The Company expects to complete enrollment of the Phase 1a trial and share data in the second half of 2024."

Enrollment status • P1 data • Acute Lymphocytic Leukemia • Hematological Malignancies • Hodgkin Lymphoma • Leukemia • Lymphoma • Oncology • Solid Tumor

SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS AND CLINICAL ACTIVITY OF KT-333, A TARGETED PROTEIN DEGRADER OF STAT3, IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC AND SOLID TUMOR CANCERS (EHA 2024) - "KT-333 is a potent and selective STAT3 degrader that has demonstrated clinicallysignificant responses including CRs and PRs in heavily pretreated cHL and CTCL patients at tolerated dosesachieving substantial target knockdown and pathway modulation, highlighting the potential ofheterobifunctional degraders for targeting previously undruggable transcription factors implicated in diseases. Accrual is ongoing, and further analyses will be presented at the meeting. **"

Clinical • IO biomarker • PK/PD data • Constipation • Cutaneous T-cell Lymphoma • Dental Disorders • Fatigue • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Leukemia • Lymphoma • Musculoskeletal Pain • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma • Prolymphocytic Leukemia • Solid Tumor • Stomatitis • T Cell Non-Hodgkin Lymphoma • IFNG • SOCS3 • STAT3

Kymera Therapeutics Presents New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting (GlobeNewswire) - P1 | N=120 | NCT05225584 | Sponsor: Kymera Therapeutics, Inc. | "The poster provides a clinical update as of June 3, 2024, from the ongoing KT-333 Phase 1 trial from 47 patients enrolled through seven dose levels (DLs) with a mean of 9.1 doses....In cHL, complete responses were achieved in two of three patients at DL4. Both responders, who had received prior treatment with at least one regimen containing a check point inhibitor as well as brentuximab vedotin, have subsequently undergone stem cell transplantation. Additionally, stable disease was observed in a third cHL patient at DL6. In NK-cell lymphoma, one complete response was achieved at DL7 in a patient with STAT3 mutation."

P1 data • Cutaneous T-cell Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma • Prolymphocytic Leukemia • Solid Tumor

Kymera Therapeutics to Present New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting (GlobeNewswire) - P1 | N=120 | NCT05225584 | Sponsor: Kymera Therapeutics, Inc. | "Kymera Therapeutics...announced that new Phase 1 data for KT-333...will be presented at the European Hematology Association...Results released in an EHA abstract today, which include a data cut-off as of February 6, 2024...The poster presentation is expected to include additional data, including PK/PD, safety and results of disease response assessments from additional patients subsequent to the abstract cut-off date...Two complete responses in two cHL patients at DL4, three partial responses in CTCL patients at DL2, 4 and 5, and stable disease in four solid tumor patients at DL3-4; KT-333 achieved maximum degradation up to 97.5%....The Phase 1a trial for KT-333 is currently ongoing. The Company expects to complete the study and share additional clinical data to inform the program’s next development steps in 2024 at an upcoming medical meeting."

P1 data • Trial status • Cutaneous T-cell Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma

Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire) - "KT-253 MDM2 Degrader: The dose escalation portion of the Phase 1a clinical trial in liquid and solid tumors is ongoing. Kymera will present KT-253 clinical data updates in a poster at the upcoming American Society of Clinical Oncology (ASCO) meeting being held May 31 – June 4, 2024, in Chicago, Illinois. The Company expects to complete the MDM2 Phase 1a study and share the full data set later in 2024 at a medical meeting. Kymera is also developing a biomarker-based patient selection strategy for subsequent development beyond Phase 1a and will present data at a medical meeting this year....The dose escalation portion of the Phase 1a clinical trial in liquid and solid tumors is ongoing. Kymera will present KT-333 clinical data updates in a poster at the upcoming European Hematology Association (EHA) meeting being held June 13-16, 2024, in Madrid, Spain. The Company expects to complete the Phase 1a study and share the full data set later in 2024 at a medical meeting."

Clinical • P1 data • Acute Lymphocytic Leukemia • Cutaneous T-cell Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma • Prolymphocytic Leukemia • Solid Tumor

E3 pairing and structural mechanisms underlying anti-tumor activity of clinical STAT3 degrader KT-333 (AACR 2024) - "In summary, we show that our clinical STAT3 degrader, KT-333, is designed and optimally paired with VHL resulting in a very stable ternary complex exhibiting properties of native protein complexes. Our data provides precise structural and molecular mechanisms behind potent, selective, consistent, and fast degradation of STAT3, and downstream mechanism of action observed in vitro and in vivo."

Clinical • Late-breaking abstract • Oncology • CRBN • STAT3

Targeting validated but un-drugged oncogenes with small molecule protein degraders (AACR 2024) - "We believe this supports KT-333's potential to address both hematological malignancies as a single agent and solid tumors as a potential novel combination therapy with anti-PD-1 or other targeted therapies.KT-253 is a highly potent heterobifunctional degrader of the murine double minute 2 (MDM2) oncoprotein, a key E3 ligase that modulates the most common tumor suppressor, p53. One patient with a partial response had MCC metastatic to abdominal lymph nodes and skin who had previously been treated with chemotherapy as well as multiple different immune checkpoint inhibitors. Lymph node metastases were responding after the first 2 cycles of treatment, as was the skin metastasis, and after 4 cycles there was an approximately 60% reduction in nodal tumor burden and resolution of the skin metastasis.In summary, these preclinical and early clinical findings support a clear degrader advantage by eliminating oncogenic proteins in key signaling pathways and validate our..."

IO biomarker • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Cutaneous T-cell Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Leukemia • Lymphoma • Merkel Cell Carcinoma • Non-melanoma Skin Cancer • Oncology • Skin Cancer • Solid Tumor • T Cell Non-Hodgkin Lymphoma • GDF15 • MDM2

Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting (GlobeNewswire) - "The Phase 1a trials for KT-333 and KT-253 are currently ongoing. The Company expects to complete both studies and share additional clinical data to inform the programs’ next development steps in 2024 at upcoming medical meetings."

P1 data • Acute Lymphocytic Leukemia • Cutaneous T-cell Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma • Prolymphocytic Leukemia • Solid Tumor

Kymera Therapeutics Outlines Key 2024 Objectives and Strategy to Progress Leading Portfolio of Immunology and Oncology Programs (GlobeNewswire) - "Kymera’s corporate goals for 2024 include:...Oncology Portfolio...(i) Complete the KT-333 (STAT3) Phase 1a study and deliver additional proof-of-concept data to inform the program’s next development steps in 2024; (ii) Complete the KT-253 (MDM2) Phase 1a study and deliver proof-of-concept data, which will inform a patient stratification strategy for the program in 2024."

P1 data • Trial status • Acute Myelogenous Leukemia • Cutaneous T-cell Lymphoma • Lymphoma • Peripheral T-cell Lymphoma • Solid Tumor

Kymera Therapeutics Presents Interim Results from STAT3 Degrader Phase 1 Clinical Trial at American Society of Hematology Annual Meeting (GlobeNewswire) - P1 | N=120 | NCT05225584 | Sponsor: Kymera Therapeutics, Inc. | "Kymera Therapeutics...shared new data from its ongoing KT-333 Phase 1 trial....The data were presented at the American Society of Hematology (ASH) h Annua65th Meeting....'We look forward to completing the dose escalation portion of the Phase 1 study in 2024 and sharing additional updates on this first-in-class program across a range of indications at future medical meetings'....A partial response (PR) was observed in one patient with Hodgkin’s lymphoma, and two PRs and one stable disease were reported among the five CTCL patients treated. Stable disease was observed in four patients with advanced solid tumors, including two head and neck cancer patients as well as patients with cholangiocarcinoma and renal cell cancer....Preclinical data demonstrating the potential of STAT3 protein degraders as a therapeutic approach in venetoclax-resistant Acute Myeloid Leukemia was also presented at the meeting."

P1 data • Preclinical • Trial status • Acute Myelogenous Leukemia • Cholangiocarcinoma • Cutaneous T-cell Lymphoma • Head and Neck Cancer • Hodgkin Lymphoma • Leukemia • Non-Hodgkin’s Lymphoma • Peripheral T-cell Lymphoma

The Leukemia & Lymphoma Society (LLS) Data and Presence at ASH Showcase Latest Blood Cancer Treatment Breakthroughs (PRNewswire) - "At the 65th Annual American Society of Hematology (ASH) Annual Meeting (December 9-12 in San Diego), The Leukemia & Lymphoma Society (LLS) will present new research findings, and proudly support more than 200 LLS-funded researchers, as well as 15 current and former LLS Therapy Acceleration Program^® (TAP) partners, who will share their study results....New data from two master clinical trials convened and led by LLS: the Pediatric Acute Leukemia Master Clinical Trial (PedAL) and the Beat AML^® Master Clinical Trial. These trials are fundamentally changing how children and adults with acute leukemias respectively are treated. New data from the LLS National Patient Registry, a project of the Michael J. Garil Patient Data Collective, which provides real-world insight into cardiotoxic adverse events in patients with chronic lymphocytic leukemia."

Clinical data • Hematological Malignancies • Lymphoma • Myelofibrosis • Non-Hodgkin’s Lymphoma • Oncology

Kymera Therapeutics Announces Third Quarter 2023 Financial Results and Provides a Business Update (GlobeNewswire) - P1 | N=120 | NCT05225584 | Sponsor: Kymera Therapeutics, Inc. "An abstract to be released by the American Society of Hematology...reports data from the KT-333 Phase 1 clinical trial through a July 10, 2023 cut-off. Of the 21 patients enrolled through dose level (DL) 5, 12 were evaluable for disease assessment, including 1 with cutaneous T-cell lymphoma (CTCL) and 1 with peripheral T-cell lymphoma (PTCL) at DL2, and 10 with solid tumors at DL1-4. One partial response was reported after 2 cycles in the CTCL patient at DL2, and stable disease was reported after 2 cycles in 3 solid tumor patients treated at DL3 and DL4. Safety and PD were consistent with previous updates."

P1 data • Cutaneous T-cell Lymphoma • Peripheral T-cell Lymphoma • Solid Tumor

Kymera Therapeutics to Present New Clinical Data from the Phase 1 Trial of STAT3 Degrader KT-333 at the ASH Annual Meeting (GlobeNewswire) - P1 | N=120 | NCT05225584 | Sponsor: Kymera Therapeutics, Inc. | "The abstract reported Phase 1 data from 21 patients enrolled through dose level (DL) 5; 12 were evaluable for disease assessment, including 1 with cutaneous T-cell lymphoma (CTCL) and 1 with peripheral T-cell lymphoma (PTCL) at DL2, and 10 with solid tumors at DL1-4. Highlights include: One partial response reported after two cycles in a CTCL patient at DL2, and stable disease reported after two cycles in three solid tumor patients treated at DL3 and DL4....No dose limiting toxicities or serious adverse events were reported; the most common adverse events were Grade 1/2 constipation, fatigue, nausea, and anemia."

P1 data • Cutaneous T-cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma

Kymera Therapeutics Receives U.S. FDA Fast Track Designation for KT-333, a First-in-Class, Investigational STAT3 Degrader for the Treatment of Relapsed/Refractory Cutaneous T-Cell Lymphoma and Relapsed/Refractory Peripheral T-Cell Lymphoma (GlobeNewswire) - "KT-333 Phase 1 oncology trial ongoing with an update including initial evaluation of its clinical antitumor activity in patients expected in the fourth quarter of 2023...Kymera Therapeutics, Inc....announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to KT-333 for the treatment of R/R Cutaneous T-cell Lymphoma (CTCL) and R/R Peripheral T-cell Lymphoma (PTCL)."

Fast track designation • P1 data • Cutaneous T-cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma

Kymera Therapeutics Announces Second Quarter 2023 Financial Results and Provides a Business Update (GlobeNewswire) - "Anticipated Upcoming Milestones...Kymera plans to share updates on its clinical-stage oncology programs later this year, including data evaluating anti-tumor activity in the target patient populations for KT-333 and KT-413 and initial safety and proof-of-mechanism data from the KT-253 Phase 1 clinical trial."

P1 data • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Cutaneous T-cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Marginal Zone Lymphoma • Myelodysplastic Syndrome • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma • Solid Tumor • T Cell Non-Hodgkin Lymphoma

Kymera Therapeutics’ STAT3 Degrader KT-333 and IRAKIMiD Degrader KT-413 Demonstrate Desired Target Knockdown and Safety with Continued Dose Escalation in Ongoing Phase I Clinical Trials (GlobeNewswire) - P1 | N=120 | NCT05225584 | Sponsor: Kymera Therapeutics, Inc. | "Kymera Therapeutics, Inc...today shared new data demonstrating that its oncology programs KT-333 and KT-413 continue to demonstrate robust dose-dependent target knockdown in ongoing Phase 1a dose escalation clinical trials, with no dose limiting toxicities (DLTs) observed. The KT-333 clinical data will be presented in a poster at the International Conference on Malignant Lymphoma (ICML) on June 16, 2023, in Lugano, Switzerland....As of the cut-off date, there were no AEs reported in DL4. Data reported from the 3 completed dose levels (DL1-3) found: Plasma exposure increased with dose, reaching levels close to those predicted to be efficacious. KT-413 achieved dose-dependent degradation of up to 70% IRAK4 and 96-100% Ikaros and Aiolos in PBMC after a single dose. Degradation profiles at DL3-4 were consistent with knockdown levels associated with profound antitumor activity in preclinical models of MYD88 mutant lymphomas."

P1 data • PK/PD data • Cutaneous T-cell Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma • Solid Tumor